0
E-MAIL THIS PAGE  |  PRINT THIS PAGE
Information for Healthcare Professionals
Once-Daily Formulation

Sustained absorption means steady, 24-hour efficacy

Steady-State Plasma Concentration
Steady-State Plasma Concentration

XANAX XR reduces the peaks that may be associated with the euphoric effects of benzodiazepines and the troughs that may be associated with breakthrough symptoms, which can lead to anticipatory anxiety.

 

Time to Peak Benefit

In One Open-Label, Switch Study for Panic Disorder: Peak Benefit Achieved as Quickly as Xanax

In One Open-Label, Switch Study for Panic Disorder: Peak Benefit Achieved as Quickly as Xanax

Nine-wk, open label, switch study of 30 patients with panic disorder, with or without agoraphobia (DSM-IV™). Dosage—patients were stabilized for 3 wk on XANAX (0.75-10 mg/d), then switched to equivalent dose of XANAX XR. Results depicted are from Wk 3 and 4 for XANAX and XANAX XR, respectively, and based on patient diary data, in which patients kept an hourly record of degree (on a 0- to 10-point scale) of anxiolytic benefit they received from each dose of medication. Diaries were compiled and analyzed to determine the time it took, in hours, to reach a maximum score after the first morning dose.

Indications >>

Important Safety Information: XANAX XR is contraindicated in patients with known sensitivity to this drug or other benzodiazepines, in patients with acute narrow-angle glaucoma, and in patients taking potent CYP3A inhibitors, such as ketoconazole and itraconazole.

Certain adverse clinical events are a direct consequence of physical dependence to alprazolam. These include a spectrum of discontinuation symptoms, the most important being the possibility of seizure.

The most commonly observed adverse events in patients treated with XANAX XR in controlled clinical trials (≥5% and at least twice the incidence observed for placebo) were: sedation (45.2% vs 22.6%), somnolence (23.0% vs 6.0%), memory impairment (15.4% vs 6.9%), dysarthria (10.9% vs 2.6%), abnormal coordination (9.4% vs 0.9%), ataxia (7.2% vs 3.2%), and decreased libido (6.0% vs 2.3%).

Please see full prescribing information for more information.


Privacy Policy    Terms of Use    Contact Pfizer

XN141121B © 2006 Pfizer Inc. All rights reserved.

The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.

The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient.